In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer.

Asmus LR, Tille JC, Kaufmann B, Melander L, Weiss T, Vessman K, Koechling W, Schwach G, Gurny R, Möller M

Journal of controlled release : official journal of the Controlled Release Society3 Dec 2012Cited by 13 (Europe PMC)

PMID23220105DOI10.1016/j.jconrel.2012.11.014PepBankPUB-23220105

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Pharmacokinetics
In rats, plasma triptorelin decreased slowly after 3 months but remained at effective concentrations for 6 months.
In plain wordsIn rats, plasma triptorelin decreased slowly after 3 months but remained at effective concentrations for 6 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePlasma concentrations
Study
ratn: not reported in source
Wistar Hannover rats
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
After 3 months, the plasma levels decreased slowly but remained at effective concentrations for the total of 6 months.
1 context sentence(design, population, supporting numbers)
Summary · context
In a second in vivo evaluation in Wistar Hannover rats, formulations containing 5% and 10% Triptorelin in the polymeric matrix released the active compound continuously for 6 months.
Report a problemFND-2322010508

Studies that did not test the peptide alone8

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

02AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Other
In rats, the 5% triptorelin hexPLA formulation released triptorelin continuously for 6 months.
In plain wordsIn rats, the 5% triptorelin hexPLA formulation released triptorelin continuously for 6 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSustained release from 5% formulation
Study
ratn: not reported in source
Wistar Hannover rats
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
In a second in vivo evaluation in Wistar Hannover rats, formulations containing 5% and 10% Triptorelin in the polymeric matrix released the active compound continuously for 6 months.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2322010504
03AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Other
In rats, the 10% triptorelin hexPLA formulation released triptorelin continuously for 6 months.
In plain wordsIn rats, the 10% triptorelin hexPLA formulation released triptorelin continuously for 6 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSustained release from 10% formulation
Study
ratn: not reported in source
Wistar Hannover rats
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
In a second in vivo evaluation in Wistar Hannover rats, formulations containing 5% and 10% Triptorelin in the polymeric matrix released the active compound continuously for 6 months.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2322010505
04AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Other
In rats, triptorelin hexPLA formulations had higher release during the initial 7 days than subsequently.
In plain wordsIn rats, triptorelin hexPLA formulations had higher release during the initial 7 days than subsequently.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseInitial release
Study
ratn: not reported in source
Wistar Hannover rats
Comparator
Later release
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
The formulations showed a higher release during the initial 7 days, which is necessary for the clinical use to down-regulate all GnRH-receptors.
1 context sentence(design, population, supporting numbers)
Summary · context
In a second in vivo evaluation in Wistar Hannover rats, formulations containing 5% and 10% Triptorelin in the polymeric matrix released the active compound continuously for 6 months.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2322010506
05AnimalNot a test of Triptorelin (Trelstar, Decapeptyl) aloneAnimal study (in vivo)Other
In rats, triptorelin hexPLA formulations showed zero order drug release over the first 3 months after the initial release phase.
In plain wordsIn rats, triptorelin hexPLA formulations showed zero order drug release over the first 3 months after the initial release phase.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableRelease kinetics
Study
ratn: not reported in source
Wistar Hannover rats
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Afterwards, a zero order drug release was observed over the first 3 months.
1 context sentence(design, population, supporting numbers)
Summary · context
In a second in vivo evaluation in Wistar Hannover rats, formulations containing 5% and 10% Triptorelin in the polymeric matrix released the active compound continuously for 6 months. The formulations showed a higher release during the initial 7 days, which is necessary for the clinical use to down-r…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2322010507
06LabNot a test of Triptorelin (Trelstar, Decapeptyl) aloneIn vitro (cell-free)Other
In laboratory tests, triptorelin retained 98% stability inside hexPLA at 5°C for at least 6 months.
In plain wordsIn lab tests, triptorelin retained 98% stability inside hexPLA at 5°C for at least 6 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableStability at low temperature
Study
n: not reported in source
Triptorelin in hexPLA matrix
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Stability
98%
5°C for at least 6 months
Source sentences
Summary
At 5°C Triptorelin showed a stability of 98% inside the polymer for at least 6 months.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2322010501
07LabNot a test of Triptorelin (Trelstar, Decapeptyl) aloneIn vitro (cell-free)Other
In laboratory tests, triptorelin stability inside hexPLA was 78% at 40°C.
In plain wordsIn lab tests, triptorelin stability inside hexPLA was 78% at 40°C.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableStability at elevated temperature
Study
n: not reported in source
Triptorelin in hexPLA matrix
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Stability
78%
40°C
Source sentences
Summary
The stability was still 78% at an elevated temperature of 40°C.
1 context sentence(design, population, supporting numbers)
Summary · context
Prior to the formulation application, the stability of Triptorelin inside the hexPLA matrix was assessed under different storage conditions and in the presence of buffer to simulate a peptide degrading environment.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2322010502
08LabNot a test of Triptorelin (Trelstar, Decapeptyl) aloneIn vitro (cell-free)Other
In laboratory tests, triptorelin inside hexPLA had 20% less degradation than triptorelin in solution.
In plain wordsIn lab tests, triptorelin inside hexPLA had 20% less degradation than triptorelin in solution.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePeptide degradation
Study
n: not reported in source
Triptorelin in hexPLA matrix
Comparator
Triptorelin solution
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
HexPLA protected the incorporated peptide from the surrounding aqueous environment, which resulted in 20% less degradation inside the polymer compared to the solution.
1 context sentence(design, population, supporting numbers)
Summary · context
Prior to the formulation application, the stability of Triptorelin inside the hexPLA matrix was assessed under different storage conditions and in the presence of buffer to simulate a peptide degrading environment.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2322010503
09LabNot a test of Triptorelin (Trelstar, Decapeptyl) aloneOther designOther
Triptorelin hexPLA formulations showed a qualitative in vitro-in vivo correlation.
In plain wordsIn lab and animal tests, triptorelin hexPLA formulations showed a qualitative correlation between laboratory and animal results.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableIn vitro-in vivo correlation
Study
n: not reported in source
In vitro-in vivo correlation of triptorelin hexPLA formulations
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Furthermore, a qualitative in vitro-in vivo correlation was observed, possibly facilitating future optimization of the Triptorelin-hexPLA sustained-release formulations.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2322010509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.